Neuromodulation Devices: World Market Prospects 2011-202102 Dec 2011 • by Natalie Aster
The US accounted for more than 88% of the global SCS market in 2010, according to Visiongain estimates. An increasing number of spinal surgery procedures have driven growth in this market. In the US, SCS is most commonly used in failed back surgery syndrome (FBSS), which is the persistent or recurrent pain felt by patients after successful spinal surgery. According to industry estimates, about 40% of patients who undergo spinal surgery are affected by FBSS. Also, predictions from leading pain societies across the USA have stated that approximately 20% of adult Americans experience chronic pain (equating to more than 60 million individuals). This statistic will further drive the SCS devices market in the US.
Neuromodulation Devices: World Market Prospects 2011-2021
Published: October 2011
Price: US$ 2,664.00
Report Sample Abstract
Medtronic Dominated the US SCS Devices Market, Closely Followed by SJM and Boston Scientific
Medtronic is the market leader in the US SCS market, accounting for 38.5% of the total US sales in 2010. According to analyses, Medtronic generated $370m from sales of its SCS devices in the US. SJM followed closely behind Medtronic with market share of 31.5%, followed by Boston Scientific with 30.0%.
Market Shares (%) of Leading Companieas in the US SCS Devices Market, 2010
Source: Visiongane 2011
More information can be found in the report “Neuromodulation Devices: World Market Prospects 2011-2021” by Visiongain.
To order the report or ask for sample pages contact email@example.com